From Target discovery to Mechanism-Driven Therapeutics
About Us
Our lab views cancer drug development not as a linear process, but as an interconnected, iterative cycle in which discovery, therapeutic engineering, and mechanistic insight continually inform one another.We begin by identifying novel therapeutic targets and rapidly translating these discoveries into antibody-based platforms, including next-generation antibody–drug conjugates (ADCs), radioimmunoconjugates, and theranostic imaging agents. In parallel, we investigate the biological mechanisms that govern therapeutic response and resistance, with a particular focus on tumor–microenvironment interactions, including complement signaling and midkine-driven resistance.By integrating target discovery, antibody engineering, molecular imaging, and mechanistic biology, we use these insights to refine target selection, optimize therapeutic design, and overcome barriers to treatment efficacy. Our long-term vision is to establish a continuous discovery-to-translation framework that enables the development of precise, biomarker-driven cancer therapies.
Our Research
Radiation sensitizing chemotherapy has shown promise in the clinic for cancer treatment. However, toxic side effects limit higher doses of systemically administered chemotherapy. In this project, radiation-sensitizing chemotherapy is being delivered specifically to cancer using antibody-drug conjugates (ADCs). We discovered a new cancer antigen that carries the ADCs specifically into cancer cells. Once the ADC is within the cell, the radiation sensitizing drug is released and enhances the efficacy of therapy. Therefore, this approach delivers radiosensitizing drugs specifically to cancer each day compared to the current once-weekly administration of systemic chemotherapy. This new paradigm of guided delivery of the ADCs to tumors treated with radiation therapy will lead to clinical trials.
Our research focuses on developing radiation-guided theranostic agents to monitor and improve cancer treatment. We investigate how radiation exposure induces specific molecular targets on cancer cells, which can be recognized by targeted antibodies for tumor imaging and therapeutic delivery. By exploring these radiation-induced changes, we aim to develop approaches that enable real-time monitoring of treatment response and support the targeted delivery of therapeutic agents, including antibody–drug conjugates and radioimmunoconjugates. Ultimately, this work seeks to advance more precise, personalized cancer treatment strategies.
We investigate midkine (MDK), a growth factor increasingly recognized for its role in cancer progression, tumor survival, and immune modulation within the tumor microenvironment. We aim to understand the molecular mechanisms regulating MDK expression and activity, its contribution to cancer cell survival and treatment resistance, and its interactions with key signaling pathways. We also explore the therapeutic potential of combining midkine inhibition with radiation therapy to enhance treatment response, overcome resistance mechanisms, and improve the effectiveness of cancer treatment.
Cancer remains a leading cause of mortality, necessitating advancements in treatment strategies, particularly for non-small cell lung cancer (NSCLC). While the current standard of care involves cytotoxic chemotherapy, external beam radiation therapies (XRT), and immunotherapy, not all patients respond optimally. The complement system, a crucial component of the innate immune system, has been implicated in both antitumor and protumorigenic responses, yet its role in modulating cancer radiotherapy remains unclear. This project investigates the impact of clinically relevant fractionated XRT on complement system regulation and its subsequent influence on cancer treatment efficacy. The aims include studying complement inhibitory proteins (CIPs) mediating the radiotherapy response, elucidating the roles of anaphylatoxins (C3a and C5a) and their receptors, and evaluating the complement system’s interplay with immune checkpoint blockade. Utilizing human and mouse lung cancer cell lines, murine models, and genetically modified mice, we conduct comprehensive in vitro and in vivo studies to assess tumor growth, immune cell responses, and systemic complement activation. This research aims to unravel the intricate interactions between complement, cancer, and XRT, providing critical insights for developing novel, combined immunotherapies against cancer.
Our Funding Sources:
Follow Us:
X: @VKapoor25
LinkedIn: www.linkedin.com/in/vaishali-kapoor-b0656730